Clinical Trial: An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Patients (Male or Female ≥18 Years) With Ph + CML in Blast Crisis

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Patients (Male or Female ≥18 Years) With Ph + CML in Blast Crisis

Brief Summary: This extension II study will allow for further follow-up of the disease under treatment with imatinib mesylate and allow the patients to continue to receive imatinib mesylate.

Detailed Summary:
Sponsor: Novartis Pharmaceuticals

Current Primary Outcome: To enable patients to have access to study drug and continue treatment [ Time Frame: until no patients are left on study ]

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Novartis

Dates:
Date Received: September 12, 2005
Date Started: August 2004
Date Completion:
Last Updated: February 21, 2017
Last Verified: February 2017